QT Imaging Holdings, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- QT Imaging Holdings, Inc. is a medical technology company specializing in the research, development, and commercialization of innovative breast and body imaging systems using quantitative transmission (QT) ultrasound technology. The company’s flagship product is the FDA-cleared QTI Breast Acoustic CT™ Scanner, which produces high-resolution, true 3D images of the breast without radiation, compression, or contrast agents, providing a safer and more comfortable diagnostic solution. QT Imaging also integrates artificial intelligence and biomarkers into its platform to enhance early detection and diagnostic accuracy, targeting women with dense breast tissue or those underserved by conventional imaging methods. The company operates primarily in the United States with expanding global distribution channels. Founded in 2012 and headquartered in Novato, California, QT Imaging redefined breast cancer screening standards by developing technology that offers MRI-comparable resolution with a pain-free and efficient imaging experience. Recent strategic developments include an $18 million private placement financing round in 2025 to accelerate growth and an exclusive U.S. distribution agreement with NXC Imaging, Inc., a Canon Medical Systems subsidiary, aimed at broadening market reach and adoption. QT Imaging also expanded its international presence through a new strategic distribution partnership in Saudi Arabia. Leadership additions such as the appointment of industry veteran Satrajit Misra as Chief Commercial Officer and Jay Jennings as Chief Financial Officer reinforce its commercial and financial capabilities. Financially, the company eliminated all short-term liabilities and forecasts robust revenue growth, targeting $18 million in 2025 revenue with plans to increase to $39 million in 2026, driven by expanded scanner shipments and strategic partnerships. QT Imaging’s latest initiatives mark a transition from primarily a scanner company to a broader SaaS and biomarker-driven medical imaging franchise, emphasizing scalable, technology-enabled healthcare solutions for improved patient outcomes worldwide. The company continues to focus on accessibility, safety, and diagnostic precision to address critical clinical gaps and improve global health outcomes in breast cancer detection and beyond. QT Imaging is publicly traded on NASDAQ under the ticker QTI following its 2024 business combination with GigCapital5, marking its transition to a publicly listed entity. This description encapsulates QT Imaging Holdings, Inc.’s core product offerings, key recent corporate changes, and operational focus in the medical imaging industry.
Company News
QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders
QT Imaging Holdings, Inc. (QTI) Q2 2026 Earnings Call Transcript
QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale
QT Imaging to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026
QT Imaging Advances Direct U.S. Commercial Strategy to Accelerate Adoption of its Breast Acoustic CT Scanner with Two Key Hires
QT Imaging Appoints Medical Imaging and Digital Health Executive Dr. Julia Albright as Chief Science Officer
QT Imaging Holdings Announces Results of 2026 Annual Stockholder Meeting
QT Imaging Receives Israeli Ministry of Health Regulatory Registration
QT Imaging Receives Israeli Ministry of Health Regulatory Registration
QT Imaging Announces Successful Completion of First FDA Routine Inspection with Zero Form 483 Observations
QT Imaging's CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week
A New Standard of Reproducibility for Quantitative Biomarkers in Breast Imaging
QT Imaging Receives Saudi Arabia FDA Regulatory Clearance
QT Imaging Set to Join the Russell Microcap® Index
QT Imaging Set to Join the Russell Microcap® Index
QT Imaging Holdings Announces Closing of $10 Million Underwritten Public Offering
QT Imaging Holdings Announces Pricing of $10 Million Underwritten Public Offering
QT Imaging Holdings Announces Pricing of $10 Million Underwritten Public Offering
QT Imaging Holdings, Inc. (QTI) Q1 2026 Earnings Call Transcript
QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million